Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact

Clinical Pathways

Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact
December 2, 2025
Guest User
EU Commission Releases Draft Annex 11: ...

12/02/2025

-

On July 7, 2025, the European Union (EU) Commission and Pharmaceutical Inspection Co-operation Scheme (PIC/S) published an updated draft of Annex 11: Computerised Systems, a supplementary guideline that is part of the Good Manufacturing Practice (GMP). Although it is GMP focused, the guiding principles of the annex can also be applied to other GxP standards.

EU Commission Releases Draft Annex 11: Computerised Systems
November 18, 2025
Guest User
Warning Letter Issued to Investigator of ...

11/18/2025

-

In July, 2025, the US Food and Drug Administration (FDA) issued a warning letter to an investigator conducting a clinical trial for pediatric participants. The warning letter was the result of a routine inspection part of the FDA’s Bioresearch Monitoring Program (BIMO) as well as the investigator’s written response to the Form FDA 483.

Warning Letter Issued to Investigator of Pediatric Study
November 6, 2025
Guest User
ISO Release DIS 9001:2026 for Quality ...

11/06/2025

-

On August 27, 2025, the International Organization for Standardization (ISO) released a Draft International Standard (DIS) for the ISO 9001:2026 Quality Management Systems (QMS) to ISO member bodies for a twelve-week review and ballot period. The goal of ISO 9001 is to help organizations create and maintain consistency of their products or services and seeks to improve and refine their internal processes and procedures to increase efficiency.

ISO Release DIS 9001:2026 for Quality Management Systems
October 30, 2025
Guest User
Problems Found in Sponsor-Investigator Led Trial

10/30/2025

-

On March 25, 2025 the U.S. Food and Drug Administration (FDA) issued a warning letter to the sponsor-investigator of a study due to objectionable conditions observed during a Bioresearch Monitoring (BIMO) Program inspection. The sponsor-investigator’s written response to the FDA Form 483 were deemed inadequate therefore the FDA issued a warning letter stating that the sponsor-investigator was noncompliant with multiple regulations within 21 CFR part 312.

Problems Found in Sponsor-Investigator Led Trial
October 8, 2025
Guest User
Sponsor BIMO Warning Letter – What is a Drug?

10/08/2025

-

On April 30th, 2025, the U.S. Food and Drug Administration (FDA) issued a warning letter and Form FDA 483 to the sponsor of a clinical investigation as the result of a Bioresearch Monitoring Program (BIMO) inspection. 40 participants were enrolled in the study and took the investigational product that the sponsor claims was to help individuals with sleeping disorders without submitting an Investigational New Drug (IND) application.

Sponsor BIMO Warning Letter – What is a Drug?
Sandra Sather
June 26, 2014

Root Cause Analysis Opportunities for GCP

Sandra Sather
June 26, 2014

06/26/2014

Root cause analysis (RCA) is an important process that is not inherent and involves scientific principles. Tools used to perform RCA (e.g. 5 Whys, fishbone diagrams, cause mapping, force field analysis, etc.) do not teach an individual how to perform RCA.

Sandra Sather
June 9, 2014

RBM: Round Table Discussion

Sandra Sather
June 9, 2014

06/09/2014

There are many opportunities where root cause analysis (RCA) can be used in running clinical trials, but not just for non-compliance root cause assessment. Another important opportunity to use root cause analysis is in an anticipatory environment.

Sandra Sather
June 9, 2014

Sponsor Monitoring Oversight: Risk-based Approach

Sandra Sather
June 9, 2014

06/09/2014

Join us tomorrow, June 10th, 1pm EST for this great course on applying quality risk management principles and tools to the oversight practices for sponsor monitoring practices for clinical trials.

Sandra Sather
May 7, 2014

WHAT DO YOU THINK?

Sandra Sather
May 7, 2014

05/07/2014

So, another topic that got a lot of time for presentations at ACRP was "remote review of source documents". In the talks there were some misunderstandings of the requirements of HIPAA.

Sandra Sather
May 6, 2014

Informed Decison Making Regarding Risk-Based Monitoring

Sandra Sather
May 6, 2014

05/06/2014

Please read a very insightful post about some of the studies looking at RBM vs. Traditional Monitoring, specifically the ADAMON and OPTIMON projects.

Newer Posts
Older Posts
 
Archive List
  • 2013 6
  • 2014 31
  • 2015 25
  • 2016 21
  • 2017 31
  • 2018 55
  • 2019 56
  • 2020 63
  • 2021 50
  • 2022 39
  • 2023 27
  • 2024 25
  • 2025 31

Subscribe to Blogs and Newsletters.

By signing up, you agree to our our Privacy Policy. You may unsubscribe from emails at any time.

Thank you! You will receive a confirmation email shortly.

Back to Top
Clinical Pathwaysinfo@clinicalpathwaysresearch.com

Cookie Notice | License Agreement | Privacy Policy | Return Policy | Terms and Conditions | Data Security Policy | Confidentiality Policy

© 2025 Clinical Pathways. All rights reserved.